載入...
Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
Aneustat (OMN54) is a multivalent, botanical anticancer candidate therapeutic. A recent Phase‐I clinical trial has indicated that it is well tolerated by patients and has immunomodulatory activity. In our study, using in vitro and in vivo prostate cancer models, we investigated Aneustat with regard...
Na minha lista:
| 發表在: | Int J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001442/ https://ncbi.nlm.nih.gov/pubmed/29441566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31310 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|